BioAge Labs' Upcoming Investor Conferences
BioAge Labs, Inc. (NASDAQ: BIOA), a dynamic player in the biotechnology sector, is ready to take significant strides in the world of investment discussions. This clinical-stage firm specializes in developing therapeutic products targeting metabolic diseases, particularly by exploring the biology of human aging.
Engagements at Major Conferences
The Company has announced its participation in several prominent investor conferences where key executives will discuss innovative approaches and scientific advancements. This is an extraordinary opportunity for potential investors and interested stakeholders to gain insights directly from the leadership team.
Citi’s 2025 Biopharma Back to School Conference
Scheduled for September, the Citi’s Biopharma Back to School Conference in Boston will see Kristen Fortney, PhD, the company’s CEO and co-founder, along with Dov Goldstein, MD, CFO, presenting during a fireside chat. This pivotal dialogue is set for September 3, where they will engage with the audience from 3:15 to 3:55 PM EDT, outlining the company’s strategic direction and upcoming milestones.
Morgan Stanley Global Healthcare Conference
Shortly after, from September 8 to 10, BioAge will also be featured at the Morgan Stanley Global Healthcare Conference in New York. Another session featuring Kristen Fortney and Dov Goldstein will take place on September 10, from 10:00 to 10:45 AM EDT. This is yet another chance to delve deeper into the company's prospects and values.
Presentation Access
For those eager to follow these discussions, live webcasts will be available for each presentation. Interested participants can register online to tune in for these insightful sessions. It’s a perfect chance for investors to better understand BioAge's operational ethos and vision.
Company Overview and Product Pipeline
BioAge is notably focused on pioneering therapeutic products that directly engage with the aging biology to mitigate metabolic diseases. Their flagship candidate, BGE-102, stands out as it is an orally available, brain-penetrating small-molecule NLRP3 inhibitor primarily targeted at obesity management. Initial trials have shown that BGE-102 effectively facilitates significant weight loss in preclinical environments, using both monotherapy approaches and in synergy with GLP-1 receptor agonists.
Current Research Initiatives
Currently, BioAge is progressing through a Phase 1 SAD/MAD trial for BGE-102, with the preliminary results expected soon, marking a substantial step in their research journey. Additionally, the firm is exploring long-acting injectable and oral small-molecule APJ agonists aimed at combating obesity further. Such aggressive research endeavors reflect the company’s commitment to harnessing human longevity insights to tackle key metabolic pathways influencing aging.
Contact Information for Inquiries
For those who wish to connect, the company has made its contact information readily available. For public relations inquiries, reach out to Chris Patil at media@bioagelabs.com. For investor relations, Dov Goldstein can be contacted at ir@bioagelabs.com. Partnership opportunities can be discussed at partnering@bioagelabs.com. More information is continually updated on their official website.
Frequently Asked Questions
What is BioAge Labs doing at the upcoming conferences?
BioAge Labs is presenting their innovative research and product pipelines that target metabolic diseases.
Who will be speaking for BioAge at the conferences?
Kristen Fortney, CEO, and Dov Goldstein, CFO, will represent BioAge Labs.
How can I access the conference presentations?
Live webcasts will be available for each presentation; registration can be completed online to participate.
What is BGE-102?
BGE-102 is BioAge’s leading product candidate, designed to act as a potent NLRP3 inhibitor for obesity treatment.
How does BioAge Labs approach its research?
BioAge employs insights from human longevity data to develop therapies targeting the aging process in relation to metabolic diseases.
